1. Scrip
  2. >>Business
  3. >>Legal & IP

IRA Updates: Lawsuit Filers Push For Fast Decisions, ICER Plans Cost Analyses

 
• By Jessica Merrill

Merck & Co. requested a swift summary judgment in the Medicare drug price negotiation case it filed in Washington, DC, while the US Chamber of Commerce filed for a preliminary injunction.

court gaval
New motions were filed in two lawsuits against the IRA • Source: Shutterstock

Merck & Co., Inc. is pushing for a fast court decision in a lawsuit it earlier filed against the US government over the implementation of a new Medicare drug price negotiation program, authorized by the Inflation Reduction Act (IRA). With just weeks to go until the US Centers for Medicare & Medicaid Services reaches key deadlines for the implementation of the program, Merck, in an 11 July court filing, urged a district court to make a summary judgement in the case.

Merck was the first plaintiff to file a lawsuit against the IRA, with legal action taken in Washington, DC, district...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Business

Finance Watch: Insmed Cashes In On Positive Data With $750m Offering

 
• By Mandy Jackson

Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.